TargetMol

Rabeprazole

Product Code:
 
TAR-T19826
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T19826-5mg5mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase.
CAS:
117976-89-3
Formula:
C18H21N3O3S
Molecular Weight:
359.44
Purity:
0.98
SMILES:
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C

References

1. Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2017 Dec 21. doi: 10.1111/hel.12456. [Epub ahead of print] PubMed PMID: 29271026. 2. Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie. 2017 Oct 26. pii: S0040-5957(17)30159-2. doi: 10.1016/j.therap.2017.08.005. [Epub ahead of print] French. PubMed PMID: 29195714. 3. Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. J Clin Pharmacol. 2017 Nov 28. doi: 10.1002/jcph.1038. [Epub ahead of print] PubMed PMID: 29193126. 4. Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2017 Nov 29. doi: 10.1007/s00535-017-1417-z. [Epub ahead of print] PubMed PMID: 29188387.